Lv6
2730 积分 2024-10-21 加入
Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia
2个月前
已完结
PD-1 Inhibitor Combined with Chemotherapy As a Salvage Therapy for Refractory DLBCL
2个月前
已关闭
Idecabtagene Vicleucel (ide-cel) CAR T-cell Therapy for Relapsed and Refractory Multiple Myeloma
3个月前
已完结
Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients
3个月前
已完结
Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial
3个月前
已关闭
A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation
3个月前
已关闭
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study
3个月前
已完结
PD-1 Inhibitor Combined with Chemotherapy As a Salvage Therapy for Refractory DLBCL
3个月前
已关闭
Dose adjusted EPOCH-R is superior to RCHOP in frontline treatment of mediastinal large B cell lymphoma
3个月前
已完结
Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial
3个月前
已关闭
皖公网安备34019202002308
